Dengue Haemorrhagic Fever (Dhf)

Nida Tabassum Khan[1*], Shabbir Hussain[1]

Department of Biotechnology, Faculty of Life Sciences & Informatics, Balochistan University of Information Technology, Engineering and Management Sciences, Takatu Campus, Airport Road, Quetta, Balochistan

*Corresponding Author: Nida tabassum khan, Department of Biotechnology, Faculty of Life Sciences & Informatics, Balochistan University of Information Technology, Engineering and Management Sciences, Takatu Campus, Airport Road, Quetta, Balochistan

Abstract

Dengue fever frequencies have been on the ascent during the most recent couple of years. In 2012, there were a sum of 21,900 cases revealed, with 35 passing's. This likened to around 76 occasions for each 100,000 people. Dengue fever is characterized with prominent signs such as stomach pain, mucosal bleeding, liver enlargement, hematocrit with diminishing platelets, plasma leakage, organ failure etc. Patients who recuperated rapidly were to have contracted dengue fever but with fewer symptoms. These patients reacted well to indicative treatment and liquid transfusions. In any case, extra disintegration of platelets was marked as extreme dengue, while recuperation was conceivable with legitimate and fast treatment

Key Words: biphasic fever; myalgia; cerebral pain; immunological; serology

Introduction

Dengue fever as the name proposes is an intense febrile sickness in which an individual experiences symptom such as serious migraine, gastro digestive upsets, dengue shock, and dengue haemorrhagic fever (DHF) [1,2]. In addition, patient's platelet count had appeared to diminish and could be utilized to anticipate the seriousness of the illness [3]. Thus, an individual's platelets profile is of most extreme significance in dengue fever [4]. Dengue is an arboviral illness and prevailed in tropical nations where over 2.5 billion individuals are in danger of contamination [5]. Dengue fever (DF) is characterized by biphasic fever, myalgia, cerebral pain, rash, leukopenia and different levels of thrombocytopenia [6]. The rate of dengue fever is assessed to have expanded to 30-crease in the past 50 years [7]. Dengue haemorrhagic fever (DHF) and dengue shock disorder (DSS) are reversible vascular intricacies of dengue fever that cause extreme thrombocytopenia and expanded vascular porousness [8]. These issues have been seen to be on the ascent lately. Platelet counts have been found to anticipate infection seriousness and are connected to expanded haematocrit, raised liver proteins, and a changed coagulation profile [9,10]. Dengue is a mosquito conceived disease one of the most essential ones that influence an enormous populace. In spite of the fact that larger part of the indicative diseases manifests themselves like a self-restricted vague febrile sickness [11]. A couple of patients in some cases progress to a more serious and in some cases hazardous sickness. A vasculopathy set apart by endothelial brokenness and plasma spillage that seems a few days into the illness, typically around the time of defervescence, is of exceptional concern [12]. This condition is more common in kids and can be serious [13]. Dengue shock disorder (DSS)

happens when the infection is sufficiently able to deliver hypovolaemic shock along with different side effects incorporate thrombocytopenia and coagulopathy, which can cause dying, and organ infections (e.g., hepatitis), which can at times prompt critical organ failures [14,15]. In people, dengue contamination causes an assortment of clinical side effects, going from an obvious or moderate illness known as dengue fever to an assortment of different conditions [16]. The serological testing technique is right now the standard indicative practice for the affirmation of dengue fever [17]. The conclusion of dengue disease was based after clinical results of blood count, prothrombin time, liver's capacity tests and serology for the assessment of antibodies were utilized [18]. Dengue haemorrhagic fever is the consequence of a perplexing cooperation of host immunological and hereditary elements with the serotype and genotype of DENV [19]. Epidemiological investigations have shown that the danger of DHF following a second disease with various serotypes is expanded by 40-80 times [20]. Mortality from DHF is age-related and primarily affects both children and the elderly [21]. In Southeast Asia, the number of DHF hospitalizations by children is disproportionately high, whereas in the United States the age distribution is more uniform [22]. Mortality from DHF can surpass 20%, yet early identification and concentrated help treatment can decrease mortality to under 19% [23]. In this way, there is a clinical need to distinguish the prescient capacity of DHF in the beginning phases of disease [24].

The underlying dengue vector known as *Aedes aegypti* mosquito has spread the sickness into the tropical and subtropical regions [25]. Dengue fever infection is a sort of RNA infection from the family *Flaviviridae* and has been isolated into four serotypes DENV 1 – 4 [26]. The

completely developed dengue infection molecule is round with being 50nm in breadth and contains different duplicates of the 3 underlying proteins a solitary duplicate of positive sense, single abandoned RNA genome and a host inferred film bilayer [27]. Viral proteases and host cut the genome in 3 primary proteins (capsid, C, prM, the forerunner of layer, M, protein and wrap, E) and seven other no underlying proteins [28]. The basis of dengue disease is the dengue explicit antigen [29]. Non-primary protein 1 (NS1) is a protein identifies dengue viral antigen [30]. Various factors impact the seriousness of ailment such as age, previous disorder, tainting serotype, or contamination brought about by a source [31]. Lately, platelet counts, for example, mean platelet volume or platelet dispersion just as platelet huge cell proportion has been found as platelet actuation markers [32]. Platelet volume is determined as MPV and is a substitute marker for bone marrow action; high MPV demonstrates improved megakaryocytic action [33]. The state of these cells changes because of platelet initiation [34]. Plateletcrit (PCT) is a platelet boundary that joins MPV and outright platelet build up to give a precise estimation of platelet biomass [35]. PCT is valuable as it helps in recognition of platelet quantitative anomaly [36].

Thrombocytopenia in Dengue

WHO have consistently included thrombocytopenia as one of the models for deciding clinical seriousness of dengue [37]. A quick fall in platelet count or a platelet count less than 150,000 for each microliter of blood are both characteristics of severe dengue [38]. On the fourth day of the illness, an active depiction of platelet includes in DHF/DF uncovered an extensive decline [39]. As a general rule, earlier examination observed that platelet counts declined humbly to extensively from the third to the seventh day of infection in grown-ups without shock, prior to getting back to normal as usual on the eighth or 10th day [40]. Platelet transfusions are normally suggested for patients who have genuine haemorrhagic side effects or have exceptionally low platelet counts, with draining or discharge, as indicated by most clinical guidelines [41]. In addition, a maculopapular rash might arise, however it generally shows up just during defervescence (days 4-7) and is missing in the majority part of the cases [42]. Side effects of the respiratory framework may likewise show up. Clinical analysis of dengue incorporates trademark lab signs, for example, thrombocytopenia and lymphopenia in the beginning phases of sickness includes that have additionally been seen in patients with SARS. Therefore, even in the early phases. clinically, dengue might be hard to recognize from SARS. [43,44]. Explicit indicative procedures are comparably restricted in their application: average dengue analytic tests, like IgM immune response recognition, may not give positive outcomes until 4-5 days following the beginning of ailment [45].

Diagnostic Test for Dengue

The lab strategies utilized for the indicative motivation behind affirming dengue infection includes infection discovery, viral nucleic corrosive antibodies or antigens or a blend of the methods [46]. After the beginning of infection, dengue antigen will be identified in plasma serum and the pieces of the tissues for a sum of 4-5 days, during the essential phases of the dengue contamination [47]. Serology is the appropriated approach for dengue diagnosis [48]. IgM is the underlying immunoglobulin isotype that shows up first and this kind of antibodies are perceptible in around half of the patients following 3 to 5 days of dengue [49]. The decision of the indicative strategies relies for the most part upon the reason for which the testing is done (e.g., immunization advancement, or clinical conclusion) the sort of lab offices accessible just as the specialized skill, cost and test assortment time [50]. Technical ability and advances are needed for tests with high explicitness and responsiveness. Infection separation and recognition of nucleic corrosive are expensive yet have the ability of being more explicit than counter acting agent discovery utilizing serological techniques [51].

Conclusion

Thus, dengue fever is caused by one of four flavivirus serotypes (DEN1, DEN2, DEN3, and DEN4) that are closely related but antigenically unique. Because cross immunity is not provided by infection with one of these serotypes, people who live in a dengue endemic area can have up to four distinct dengue illnesses in their lifetime.

References

1. Gubler, D. J. (2006, October). Dengue/dengue haemorrhagic fever: history and current status. In Novartis foundation symposium (Vol. 277, p. 3). Chichester; New York; John Wiley; 1999.

2. Ocazionez, R. E., Cortés, F. M., Villar, L. A., & Gómez, S. Y. (2006). Temporal distribution of dengue virus serotypes in Colombian endemic area and dengue incidence: re-introduction of dengue-3 associated to mild febrile illness and primary infection. Memorias do Instituto Oswaldo Cruz, 101, 725-731.

3. Kularatne, S. A. (2015). Dengue fever. Bmj, 351.

4. Derouich, M., Boutayeb, A., & Twizell, E. H. (2003). A model of dengue fever. BioMedical Engineering OnLine, 2(1), 1-10.

5. Guha-Sapir, D., & Schimmer, B. (2005). Dengue fever: new paradigms for a changing epidemiology. Emerging themes in epidemiology, 2(1), 1-10.

6. Effler, P. V., Pang, L., Kitsutani, P., Vorndam, V., Nakata, M., Ayers, T., ... & Hawaii Dengue Outbreak Investigation Team. (2005). Dengue fever, hawaii, 2001–2002. Emerging infectious diseases, 11(5), 742.

7. Waterman, S. H., & Gubler, D. J. (1989). Dengue fever. Clinics in dermatology, 7(1), 117-122.

8. Zhang, H., Zhou, Y. P., Peng, H. J., Zhang, X. H., Zhou, F. Y., Liu, Z. H., & Chen, X. G. (2014). Predictive symptoms and signs of severe dengue disease for patients with dengue fever: a meta-analysis. BioMed research international, 2014.

9. Cobra, C., Rigau-Pérez, J. G., Kuno, G., & Vomdam, V. (1995). Symptoms of dengue fever in relation to host immunologic response and virus serotype, Puerto Rico, 1990–1991. American journal of epidemiology, 142(11), 1204-1211.

10. Yeh, C. Y., Chen, P. L., Chuang, K. T., Shu, Y. C., Chien, Y. W., Perng, G. C., ... & Ko, N. Y. (2017). Symptoms associated with adverse dengue fever prognoses at the time of reporting in the 2015 dengue outbreak in Taiwan. PLoS neglected tropical diseases, 11(12), e0006091.

11. Daniel, R., & Philip, A. Z. (2005). A study of clinical profile of dengue fever in Kollam, Kerala, India.

12. Schaefer, T. J., Panda, P. K., & Wolford, R. W. (2021). Dengue fever. StatPearls [Internet].

13. Tiga-Loza, D. C., Martínez-Vega, R. A., Undurraga, E. A., Tschampl, C. A., Shepard, D. S., & Ramos-Castañeda, J. (2020). Persistence of symptoms in dengue patients: a clinical cohort study. Transactions of The Royal Society of Tropical Medicine and Hygiene, 114(5), 355-364.

14. Teixeira, L. D. A. S., Nogueira, F. P. D. S., & Nascentes, G. A. N. (2017). Prospective study of patients with persistent symptoms of dengue in Brazil. Revista do Instituto de Medicina Tropical de São Paulo, 59.

15. Maroun, S. L., Marliere, R. C., Barcellus, R. C., Barbosa, C. N., Ramos, J. R., & Moreira, M. E. (2008). Case report: vertical dengue infection. Jornal de pediatria, 84, 556-559.

16. Heilman, J. M., De Wolff, J., Beards, G. M., & Basden, B. J. (2014). Dengue fever: a Wikipedia clinical review. Open medicine, 8(4), e105.

17. De Paula, S. O., & Fonseca, B. A. L. D. (2004). Dengue: a review of the laboratory tests a clinician must know to achieve a correct diagnosis. Brazilian Journal of Infectious Diseases, 8, 390-398.

18. Teles, F. R. R., Prazeres, D. M. F., & Lima-Filho, J. L. (2005). Trends in dengue diagnosis. Reviews in medical virology, 15(5), 287-302.

19. Guzmán, M. G., & Kouri, G. (2002). Dengue: an update. The Lancet infectious diseases, 2(1), 33-42.

20. Ferreira, G. L. (2012). Global dengue epidemiology trends. Revista do Instituto de Medicina Tropical de São Paulo, 54, 5-6.

21. Jing, Q., & Wang, M. (2019). Dengue epidemiology. Global Health Journal, 3(2), 37-45.

22. Wilder-Smith, A., Ooi, E. E., Vasudevan, S. G., & Gubler, D. J. (2010). Update on dengue: epidemiology, virus evolution, antiviral drugs, and vaccine development. Current infectious disease reports, 12(3), 157-164.

23. Wilson, M. E., & Chen, L. H. (2015). Dengue: update on epidemiology. Current infectious disease reports, 17(1), 1-8.

24. Bhatia, R., Dash, A. P., & Sunyoto, T. (2013). Changing epidemiology of dengue in South-East Asia. WHO South-East Asia Journal of Public Health, 2(1), 23.

25. Jansen, C. C., & Beebe, N. W. (2010). The dengue vector Aedes aegypti: what comes next. Microbes and infection, 12(4), 272-279.

26. Harrington, L. C., Scott, T. W., Lerdthusnee, K., Coleman, R. C., Costero, A., Clark, G. G., ... & Edman, J. D. (2005). Dispersal of the dengue vector Aedes aegypti within and between rural communities. The American journal of tropical medicine and hygiene, 72(2), 209-220.

27. De Valdez, M. R. W., Nimmo, D., Betz, J., Gong, H. F., James, A. A., Alphey, L., & Black, W. C. (2011). Genetic elimination of dengue vector mosquitoes. Proceedings of the National Academy of Sciences, 108(12), 4772-4775.

28. Kuberski, T. T., & Rosen, L. (1977). A simple technique for the detection of dengue antigen in mosquitoes by immunofluorescence. The American journal of tropical medicine and hygiene, 26(3), 533-537.

29. Miagostovich, M. P., Ramos, R. G., Nicol, A. F., Nogueira, R. M., Cuzzi-Maya, T., Oliveira, A. V., ... & Schatzmayr, H. G. (1997). Retrospective study on dengue fatal cases. Clinical neuropathology, 16(4), 204-208.

30. Kassim, F. M., Izati, M. N., TgRogayah, T. A., Apandi, Y. M., & Saat, Z. (2011). Use of dengue NS1 antigen for early diagnosis of dengue virus infection. Southeast Asian J Trop Med Public Health, 42(3), 562-9.

31. Halstead, S. B. (2002). Dengue. Current opinion in infectious diseases, 15(5), 471-476.

32. Banerjee, M., Chatterjee, T., Choudhary, G. S., Srinivas, V., & Kataria, V. K. (2008). Dengue: a clinicohaematological profile. Medical Journal Armed Forces India, 64(4), 333-336.

33. Mittal, H., Faridi, M. M. A., Arora, S. K., & Patil, R. (2012). Clinicohematological profile and platelet trends in children with dengue during 2010 epidemic in north India. The Indian Journal of Pediatrics, 79(4), 467-471.

34. Deshwal, R., Qureshi, M. I., & Singh, R. (2015). Clinical and laboratory profile of dengue fever. J Assoc Physicians India, 63(12), 30-32.

35. Mukker, P., & Kiran, S. (2018). Platelet indices evaluation in patients with dengue fever. Int J Res Med Sci, 6(6), 2054-9.

36. Hottz, E. D., Medeiros-de-Moraes, I. M., Vieira-de-Abreu, A., de Assis, E. F., Vals-de-Souza, R., Castro-Faria-Neto, H. C., ... & Bozza, P. T. (2014). Platelet activation and apoptosis modulate monocyte inflammatory responses in dengue. The Journal of Immunology, 193(4), 1864-1872.

37. Huang, K. J., Li, S. Y. J., Chen, S. C., Liu, H. S., Lin, Y. S., Yeh, T. M., ... & Lei, H. Y. (2000). Manifestation of thrombocytopenia in dengue-2-virus-infected mice. Journal of General Virology, 81(9), 2177-2182.

38. Azeredo, E. L. D., Monteiro, R. Q., & de-Oliveira Pinto, L. M. (2015). Thrombocytopenia in dengue: interrelationship between virus and the imbalance between coagulation and fibrinolysis and inflammatory mediators. Mediators of inflammation, 2015.

39. Ojha, A., Nandi, D., Batra, H., Singhal, R., Annarapu, G. K., Bhattacharyya, S., ... & Guchhait, P. (2017). Platelet activation determines the severity of thrombocytopenia in dengue infection. Scientific reports, 7(1), 1-10.

40. Dinesh, N., & Patil, V. D. (2006). Persistent thrombocytopenia after dengue hemorrhagic fever. Indian pediatrics, 43(11), 1010.

41. Jyothi, P., & Metri, B. C. (2015). Correlation of serological markers and platelet count in the diagnosis of Dengue virus infection. Advanced biomedical research, 4.

42. Srichaikul, T., & Nimmannitya, S. (2000). Haematology in dengue and dengue haemorrhagic fever. Best Practice & Research Clinical Haematology, 13(2), 261-276.

43. Su, I. J. (2008, March). How the SARS experience has helped preparations for future outbreaks: The Taiwan experience, with emphasis on the successful control of institutional outbreak of influenza in 2003/2004 using a stockpile of antivirals. In Novel and Re-Emerging Respiratory Viral Diseases: Novartis Foundation Symposium 290 (Vol. 290, pp. 89-98). Chichester, UK: John Wiley & Sons, Ltd.

44. Islam, M. R., Hossan, A., Uddin, M. N., & Hasan, M. T. (2020). COVID-19 and Dengue Combination Dilemma: A Case of Probable Dengue False Positivity in a COVID 19 Patient. Journal of Bangladesh College of Physicians and Surgeons, 133-135.

45. Venkatesh, U., Ish, P., Kumari, S., Gupta, N., & Sharma, A. (2021). Severe Acute Respiratory Syndrome Coronavirus 2 and Dengue Virus Co-infection: Indian Perspectives. Disaster medicine and public health preparedness, 1-3.

46. Grande, A. J., Reid, H., Thomas, E., Foster, C., & Darton, T. C. (2016). Tourniquet test for dengue diagnosis: systematic review and meta-analysis of diagnostic test accuracy. PLoS neglected tropical diseases, 10(8), e0004888.

47. Peeling, R. W., Artsob, H., Pelegrino, J. L., Buchy, P., Cardosa, M. J., Devi, S., ... & Yoksan, S. (2010). Evaluation of diagnostic tests: dengue. Nature Reviews Microbiology, 8(12), S30-S37.

48. Tang, K. F., & Ooi, E. E. (2012). Diagnosis of dengue: an update. Expert review of anti-infective therapy, 10(8), 895-907.

49. De Paula, S. O., & Fonseca, B. A. L. D. (2004). Dengue: a review of the laboratory tests a clinician must know to achieve a correct diagnosis. Brazilian Journal of Infectious Diseases, 8, 390-398.

50. de la Cruz Hernández, S. I., Mateos, S. G., Aguilar, H. F., Martinez, I. L., Aranda, C. A., Ludert, J. E., & Del Angel, R. M. (2012). Evaluation of a novel commercial rapid test for dengue diagnosis based on specific IgA detection. Diagnostic microbiology and infectious disease, 72(2), 150-155.

51. Shu, P. Y., & Huang, J. H. (2004). Current advances in dengue diagnosis. Clinical and Vaccine Immunology, 11(4), 642-650.